158 related articles for article (PubMed ID: 34149846)
1. Longer Time to Reach Excellent Response to Treatment in Familial Versus Sporadic Non-medullary Thyroid Cancer (NMTC): A Matched Case-Control Study.
Shafiei S; Sadrolodabaei M; Aghaei A; Ayati N; Zare Namdar S; Hemati D; Zakavi SR
Int J Endocrinol Metab; 2021 Apr; 19(2):e108781. PubMed ID: 34149846
[TBL] [Abstract][Full Text] [Related]
2. Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients.
Capezzone M; Sagnella A; Cantara S; Fralassi N; Maino F; Forleo R; Brilli L; Pilli T; Cartocci A; Castagna MG
Front Endocrinol (Lausanne); 2022; 13():845954. PubMed ID: 35311228
[TBL] [Abstract][Full Text] [Related]
3. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
[TBL] [Abstract][Full Text] [Related]
4. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
5. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Semin Surg Oncol; 1999; 16(1):16-8. PubMed ID: 9890735
[TBL] [Abstract][Full Text] [Related]
6. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
7. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
[TBL] [Abstract][Full Text] [Related]
8. Familial Nonmedullary Thyroid Carcinoma: A Retrospective Analysis of 117 Families.
Zhang YB; Wang XX; Zhang XW; Li ZJ; Liu J; Xu ZG; Tang PZ
Chin Med J (Engl); 2018 Feb; 131(4):395-401. PubMed ID: 29451143
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC Consortium.
Lesueur F; Stark M; Tocco T; Ayadi H; Delisle MJ; Goldgar DE; Schlumberger M; Romeo G; Canzian F
J Clin Endocrinol Metab; 1999 Jun; 84(6):2157-62. PubMed ID: 10372725
[TBL] [Abstract][Full Text] [Related]
10. Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.
Crezee T; Tesselaar MH; Nagarajah J; Corver WE; Morreau J; Pritchard C; Kimura S; Kuiper JG; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
Cell Oncol (Dordr); 2021 Jun; 44(3):611-625. PubMed ID: 33534128
[TBL] [Abstract][Full Text] [Related]
11. Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries.
Fallah M; Pukkala E; Tryggvadottir L; Olsen JH; Tretli S; Sundquist K; Hemminki K
J Med Genet; 2013 Jun; 50(6):373-82. PubMed ID: 23585692
[TBL] [Abstract][Full Text] [Related]
12. Genetic predisposition for nonmedullary thyroid cancer.
Nagy R; Ringel MD
Horm Cancer; 2015 Feb; 6(1):13-20. PubMed ID: 25338077
[TBL] [Abstract][Full Text] [Related]
13. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
14. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
[TBL] [Abstract][Full Text] [Related]
15. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
16. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
17. Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study.
Lin HT; Liu FC; Lin SF; Kuo CF; Chen YY; Yu HP
J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32333767
[TBL] [Abstract][Full Text] [Related]
18. The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer.
Sahasrabudhe R; Stultz J; Williamson J; Lott P; Estrada A; Bohorquez M; Palles C; Polanco-Echeverry G; Jaeger E; Martin L; Magdalena Echeverry M; Tomlinson I; Carvajal-Carmona LG;
J Clin Endocrinol Metab; 2016 Mar; 10(3):1098-1103. PubMed ID: 26691890
[TBL] [Abstract][Full Text] [Related]
19. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
20. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]